New insights into the role of fibroblast growth factor 23 in chronic kidney disease

Journal of Nephrology

Volumn 23, Issue 6, 2010, Pages 619-625

  Nakai, Kentaro ^a   Komaba, Hirotaka ^a,b   Fukagawa, Masafumi ^a,b  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; FGF23; Klotho; Phosphate; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1C; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; UNCLASSIFIED DRUG; VITAMIN D;

BONE DISEASE; CHRONIC KIDNEY DISEASE; DIALYSIS; DISEASE MARKER; ESTROGEN ACTIVITY; HUMAN; HYPOPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NONHUMAN; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; POSTOPERATIVE COMPLICATION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM;

ANIMALS; CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PHOSPHATES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; VITAMIN D;

EID: 78549244818     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009;24:1506-1523.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218. (Pubitemid 39031360)
3. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118:3820-3828.
4. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435. (Pubitemid 38787398)
5. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor- independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088-F1095.
6. Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291:E38-E49. (Pubitemid 44035308)
7. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277:494-498.
8. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345-348.
9. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002;143:3179-3182. (Pubitemid 34809892)
10. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomaldominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60:2079-2086. (Pubitemid 33070451)
11. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38:1248-1250.
12. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003;278:37419-37426. (Pubitemid 37175262)
13. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500-6505.
14. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3087-3094.
15. Bai X, Miao D, Li J, et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;145:5269-5279. (Pubitemid 39551149)
16. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561-568. (Pubitemid 38542505)
17. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421-432. (Pubitemid 39576657)
18. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004;36:579-581.
19. Benet-Pagès A, Orlik P, Strom TM, et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005;14:385-390. (Pubitemid 40220655)
20. Larsson T, Davis SI, Garringer HJ, et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology. 2005;146:3883-3891. (Pubitemid 41178968)
21. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003-4008. (Pubitemid 350224109)
22. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195:125-131. (Pubitemid 350056006)
23. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010;77:292-298.
24. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem. 2006;281:6120-6123. (Pubitemid 43847540)
25. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770-774. (Pubitemid 44949607)
26. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51.
27. Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol. 2008;19:2342-2350.
28. Perwad F, Azam N, Zhang MY, et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005;146:5358-5364. (Pubitemid 41653049)
29. Nishida Y, Taketani Y, Yamanaka-Okumura H, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 2006;70:2141-2147. (Pubitemid 44871378)
30. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor- 23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90:1519-1524. (Pubitemid 40464013)
31. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305-1315. (Pubitemid 43673410)
32. Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 2005;101:c94-c99. (Pubitemid 41208897)
33. Carrillo-López N, Román-García P, Rodríguez-Rebollar A, et al. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol. 2009;20:2009-2017.
34. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94:2332-2337.
35. Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45:814-816.
36. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272-2279. (Pubitemid 37449564)
37. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004;65:1943-1946.
38. Shigematsu T, Yamashita T, Fukumoto S, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44:250-256. (Pubitemid 38962552)
39. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010;95:578-585.
40. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor- 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205-2215. (Pubitemid 41716454)
41. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.
42. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009;24:2792-2796.
43. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385-390.
44. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009;337:116-122.
45. Gutiérrez OM, Januzzi J, Isakova T, et al. Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545-2552.
46. Isakova T, Gutiérrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int. 2009;76:705-716.
47. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005;67:1171-1178. (Pubitemid 41623344)
48. Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF- 23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 2005;67:1120-1125. (Pubitemid 41623338)
49. Kifor O, Moore FD Jr, Wang P, et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:1598-1606.
50. Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328-336. (Pubitemid 27064555)
51. Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436-1443. (Pubitemid 23273922)
52. Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000;58:1980-1986.
53. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. 2002;62:1196-1207.
54. Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010;77:232-238.
55. Kumata C, Mizobuchi M, Ogata H, et al. Involvement of α-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol. 2010;31:230-238.
56. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77:211-218.
57. Canalejo R, Canalejo A, Martinez-Moreno JM, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010;21:1125-1135.
58. Levi M. Post-transplant hypophosphatemia. Kidney Int. 2001;59:2377-2387.
59. Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int. 2006;70:1486-1494.
60. Evenepoel P, Naesens M, Claes K, et al. Tertiary 'hyper-phosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant. 2007;7:1193-1200.
61. Evenepoel P, Meijers BK, de Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008;3:1829-1836.
62. Sato T, Fukagawa M, Uchida K, et al. 1,25-Dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine. Clin Transplant. 2009;23:368-374.
63. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone. 2004;35:1192-1199.
64. Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24:1879-1888.